

Special Issue

The Development of Echocardiography in Heart Disease

Message from the Guest Editors

Since Inge Edler and Helmut Hertz presented M-mode echocardiography in 1953 and marked the beginning of a new diagnostic non-invasive technique, the tremendous development of technologies has made this method one of the most important in cardiology, everyday clinical practice, and scientific research. New technologies such as stress and contrast echocardiography, speckle tracking echocardiography, and 3D echocardiography permit us to detect subclinical changes in the heart and diagnose heart pathologies that earlier remained undiagnosed or detected with the help of complex invasive methods. The wide range of all now available echocardiographic techniques, together with fused technologies, not only markedly improved the diagnostic process but also opened the possibilities for personalized management owing to the revealed subtle echocardiographic data as well as permitted the performance of different interventional procedures relying on echocardiographic images. This Special Issue is open for scientific research on different applications of echocardiography. Original research papers, systematic reviews, and case reports are welcome.

Guest Editors

Prof. Dr. Jolanta Justina Vaskelyte

Dr. Egle Rumbinaite

Dr. Vaida Mizariene

Deadline for manuscript submissions

20 June 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/197401

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://jpm.mdpi.com)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).